GlassScriptPhysician profile
Kelsey Russell Key
NPI 1225734999
$1,517.76
in general payments reported to CMS, 2019-2025
19 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $450 · 2024: $590 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.99 | 2023-2025 | |
| Novo Nordisk INC | $273.79 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $186.91 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $141.28 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Paratek Pharmaceuticals, INC. | $88.19 | 2023-2025 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $58.47 | 2023-2024 | Quviviq |
| Pfizer INC. | $57.95 | 2024 | |
| Exact Sciences Corporation | $47.94 | 2023-2024 | Cologuard Collection Kit |
| Alk-Abello, INC | $46.55 | 2023-2024 | Ragwitek, Odactra, Grastek |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.46 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $34.34 | 2023 | Sunosi |
| Ascend Therapeutics US, LLC | $22.21 | 2024 | |
| Astellas Pharma US INC | $20.39 | 2024 | Veozah |
| Dexcom, INC. | $18.27 | 2023 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $17.53 | 2023 | Kloxxado, Ryaltris, Mitigare |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.38 | 2023 | |
| Currax Pharmaceuticals LLC | $15.36 | 2024 | Contrave |
| Esperion Therapeutics, INC. | $13.90 | 2024 | Nexletol |
| Corcept Therapeutics | $12.85 | 2023 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Key listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.